Pliant Therapeutics (NASDAQ: PLRX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.780 | ||||||
REV | 1.249M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Pliant Therapeutics (NASDAQ: PLRX) through any online brokerage.
Other companies in Pliant Therapeutics’s space includes: Aerie Pharmaceuticals (NASDAQ:AERI), Verona Pharma (NASDAQ:VRNA), CymaBay Therapeutics (NASDAQ:CBAY), Provention Bio (NASDAQ:PRVB) and Rani Therapeutics Hldgs (NASDAQ:RANI).
The latest price target for Pliant Therapeutics (NASDAQ: PLRX) was reported by Piper Sandler on Wednesday, May 18, 2022. The analyst firm set a price target for 27.00 expecting PLRX to rise to within 12 months (a possible 444.35% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Pliant Therapeutics (NASDAQ: PLRX) is $4.96 last updated May 20, 2022, 8:00 PM UTC.
There are no upcoming dividends for Pliant Therapeutics.
Pliant Therapeutics’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Pliant Therapeutics.
Pliant Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.